Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ULTIMOVACS-ASA-59297686/news/Ultimovacs-ASA-UV1-in-Combination-with-Pembrolizumab-Shows-60-Objective-Response-Rate-in-Advance-33381713/?utm_source=whatsapp&utm_medium=social&utm_campaign=share